Lipotoxicity and metabolic disorders at obesity

Lipotoxicity and metabolic disorders at obesity

The aim of review. To discuss relation of obesity to phenomena of insulin resistance and lipotoxicity, and to demonstrate main therapeutic directions of their correction.Original positions. The most serious metabolic disorders related to obesity, include non-alcoholic fatty liver disease (NAFLD), di...

Full description

Saved in:

Bibliographic Details
Main Authors:	V. T. Ivashkin, M. V. Mayevskaya
Format:	Article
Language:	Russian
Published:	Gastro LLC 2010-02-01
Series:	Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:	non-alcoholic fatty liver disease obesity insulin resistance lipotoxicity nuclear receptors treatment
Online Access:	https://www.gastro-j.ru/jour/article/view/1483
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Prevalence and association of non-alcoholic fatty liver disease and insulin resistance among non-diabetic obese, overweight, and metabolically obese normal-weight adult patients attending at a tertiary care hospital in Eastern India
by: Samik Pramanik, et al.
Published: (2025-02-01)

Pathogenic role of lipids in non-alcoholic fatty liver disease
by: Yu. O. Shulpekova
Published: (2012-02-01)

The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease
by: Sun Xin, et al.
Published: (2017-03-01)

Prevalence of non-alcoholic fatty liver disease at obesity and its interrelation with cardio-vascular disease and 2nd type diabetes mellitus risk factors
by: G. A. Melnichenko, et al.
Published: (2012-04-01)

Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease
by: V. T. Ivashkin, et al.
Published: (2022-12-01)

Non-Alcoholic Fatty Liver Disease, Bile Acids and Intestinal Microbiota
by: R. V. Maslennikov, et al.
Published: (2018-09-01)

Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Jessica M. Rubino, et al.
Published: (2025-01-01)

The Safety and Efficacy of Dietary Epigallocatechin Gallate Supplementation for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: Recent Updates
by: Ruike Yan, et al.
Published: (2025-01-01)

Epidemiologic features of non-alcoholic fatty liver disease in Russia
by: O. M. Drapkina, et al.
Published: (2014-10-01)

Practical Aspects of Clinical Manifestations, Pathogenesis and Therapy of Alcoholic Liver Disease and Non-alcoholic Fatty Liver Disease: Expert Opinion
by: V. V. Tsukanov, et al.
Published: (2023-11-01)

Perioperative treatment with cilostazol reverses steatosis and improves liver regeneration after major hepatectomy in a steatotic rat model
by: Sebastian Holländer, et al.
Published: (2025-01-01)

Liver and Nutrition. An Optimal Diet for Non-Alcoholic Fatty Liver Disease
by: M. V. Mayevskaya, et al.
Published: (2018-11-01)

Correlation between liver fibrosis in non-alcoholic fatty liver disease and insulin resistance indicators: a cross-sectional study from NHANES 2017–2020
by: Bo Yang, et al.
Published: (2025-01-01)

Profile of Children With Non-alcoholic Fatty Liver Disease Referred to a Hospital in Iran
by: Amin Ghanbari, et al.
Published: (2024-12-01)

The value of sex hormones and sex hormone-binding globulin in metabolic dysfunction-associated fatty liver disease among boys with obesity
by: Ying Wang, et al.
Published: (2025-02-01)

Modulatory effects of Lactiplantibacillus plantarum on chronic metabolic diseases
by: Lei Tian, et al.
Published: (2023-07-01)

Antioxidants in the Treatment of Chronic Diffuse Liver Diseases (the Results of the “MAXAR” Observational Program)
by: M. V. Mayevskaya, et al.
Published: (2018-11-01)

Metabolic and Genetic Determinants of Lipid Metabolism Disruption in Non-Alcoholic Fatty Liver Disease
by: O. Yu. Kytikova, et al.
Published: (2020-05-01)

Phenotypes of Non-Alcoholic Fatty Liver Disease in Different Regions of the Russian Federation, Diagnostic and Therapeutic Approach in Clinical Practice
by: V. T. Ivashkin, et al.
Published: (2023-08-01)

PEDF Overexpression Ameliorates Cardiac Lipotoxicity in Diabetic Cardiomyopathy via Regulation of Energy Metabolism
by: Mao T, et al.
Published: (2025-01-01)

Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review
by: Hongcai Li, et al.
Published: (2025-02-01)

Association of leptin receptor Gln223Arg genetic polymorphism with obesity and non-alcoholic fatty liver disease
by: A. V. Morozova, et al.
Published: (2014-09-01)

Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
by: Gong Feng, et al.
Published: (2025-03-01)

Risk of Cirrhosis in Patients with Non-alcoholic Fatty Liver Disease and Previous Viral Hepatitis B
by: S. N. Batskikh, et al.
Published: (2020-09-01)

Improvement of non-alcoholic fatty liver disease treatment
by: P. I. Seliverstov, et al.
Published: (2014-10-01)

Clinical and Pathogenetic Parallels of Nonalcoholic Fatty Liver Disease and Gallstone Disease
by: Aleksey O. Bueverov
Published: (2019-03-01)

Non-Alcoholic Fatty Liver Disease in Cardiac Patients with Overweight and Obesity
by: I. V. Logacheva, et al.
Published: (2019-01-01)

Indicators of Glucose Metabolism in Children and Adolescents Characterized as Having “Metabolically Healthy” and “Metabolically Unhealthy” Obesity
by: Maria Baltogianni, et al.
Published: (2025-01-01)

Associations between Chinese Visceral Adiposity Index and the Risk of Metabolic Dysfunction-associated Steatotic Liver Disease and Liver Fibrosis: A Large Cross-sectional Study
by: Hui Liu, et al.
Published: (2025-01-01)

Intrahepatic Cholestasis in Non-Alcoholic Fatty Liver Disease: Pathogenesis and Role of Ademetionine in Treatment
by: Ye. N. Shirokova
Published: (2023-08-01)

Human umbilical cord derived-mesenchymal stem cells alleviate lipid metabolism disturbances of hepatocytes via mitochondrial transport
by: Jing Xue, et al.
Published: (2025-01-01)

An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non-Alcoholic Fatty Liver Disease: Results of the USPEH Study
by: M. V. Mayevskaya, et al.
Published: (2020-01-01)

Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
by: A. E. Bagriy, et al.
Published: (2021-06-01)

Prevalence and factors associated with non-alcoholic fatty liver disease among women with polycystic ovary syndrome
by: Maria Elisa Franciscatto, et al.
Published: (2025-01-01)

The rationale for the aggressive progression of MASLD in patients with type 2 diabetes
by: Valeria Michelle Fernández-Garibay, et al.
Published: (2025-01-01)

Effect of weight loss on the course of non-alcoholic fatty liver disease: results of 6-month follow-up
by: L. V. Chesnokova, et al.
Published: (2015-03-01)

Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation
by: K. L. Raikhelson, et al.
Published: (2024-05-01)

Dose-response relationship between the fatty liver index and asthma risk: NHANES 2001~2018
by: Tengfei Sun, et al.
Published: (2025-02-01)

A prediction model of liver fat fraction and presence of non-alcoholic fatty liver disease (NAFLD) among patients with overweight or obesity
by: Jie Chen, et al.
Published: (2023-10-01)

Liver macrophage activation: Relation with hepatic histopathological changes in patients with metabolic associated steatotic liver disease
by: Doaa H. Hegazy, et al.
Published: (2024-06-01)